Recorded fact · drug.label_indication
drug.label_indication for dasatinib|chronic-myeloid-leukemia
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact b0c4570a resolves to.
The record
| Fact id | b0c4570afe0fb81b4d0ebcf8 |
|---|---|
| Entity | drug: dasatinib|chronic-myeloid-leukemia |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260305 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 45cb20df6813bfdc029a07a6f1a8ed98e6027d6cf3b8f9d327a0e455aaf14bfa.
The value
{
"ingredient": "Dasatinib",
"conditionId": "chronic-myeloid-leukemia",
"conditionName": "Chronic Myeloid Leukemia",
"matchedAlias": "chronic myeloid leukemia",
"context": "indication",
"brand": "Dasatinib",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4",
"labelEffectiveTime": "20260305",
"labelsRead": 12,
"labelsNaming": 12,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 869b29c471119733a34fed72241b8c6b69ba2a1f07821f2bba21cb3279a4982f.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.